We propose a new approach of complement‐mediated destructive tumour cell targeting by generating immunoconjugates harbouring multimeric (a) factor H‐related protein 4 (FHR4)‐complement effector functions with; (b) VHH anti‐HER2 targeting functions. Here, ERBB2 is linked to neoplasm.